Health Care & Life Sciences » Biotechnology | Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
1,780.50
282.00
388.00
185.00
1,120
Cost of Goods Sold (COGS) incl. D&A
587.20
-
-
-
-
-
Gross Income
587.20
-
-
-
-
-
SG&A Expense
9,275.40
15,739.80
48,218.00
66,462.00
84,008.00
89,888
EBIT
9,862.60
14,625.90
49,135.00
68,380.00
87,387.00
95,466
Unusual Expense
-
67,582.70
-
-
1,786.00
-
Non Operating Income/Expense
1,940.70
-
42.00
10.00
11.00
10
Interest Expense
50.70
1,791.20
12.00
1,760.00
3,672.00
4,199
Pretax Income
7,968.80
83,964.80
48,548.00
69,241.00
91,779.00
98,036
Consolidated Net Income
7,968.80
83,964.80
48,548.00
69,241.00
91,779.00
98,036
Net Income
7,968.80
83,964.80
48,548.00
69,241.00
91,779.00
98,036
Net Income After Extraordinaries
7,968.80
83,964.80
48,548.00
69,241.00
91,779.00
98,036
Net Income Available to Common
9,062.40
85,397.20
48,548.00
69,241.00
91,779.00
98,036
EPS (Basic)
3.09
34.04
1.84
2.57
2.89
2.44
Basic Shares Outstanding
26,952.10
2,509.00
26,346.60
26,950.90
31,714.20
40,230.60
EPS (Diluted)
0.34
34.04
1.84
2.57
2.89
2.44
Diluted Shares Outstanding
26,952.10
2,509.00
26,346.60
26,950.90
31,714.20
40,230.60
EBITDA
9,275.40
13,959.30
47,936.00
66,074.00
83,823.00
88,768
Non-Operating Interest Income
3.90
35.00
641.00
909.00
1,055.00
1,639
Preferred Dividends
1,093.60
1,432.40
-
-
-
-

About Bellicum Pharmaceuticals

View Profile
Address
Life Science Plaza
Houston Texas 77030
United States
Employees -
Website http://www.bellicum.com
Updated 07/08/2019
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.